Belize vs Libya: Cause of death, by non-communicable diseases, ages 60+, female
Belize
73.7%
in 2021
Libya
73.9%
in 2021
Belize rank
97th
Libya rank
96th
Cause of death, by non-communicable diseases, ages 60+, female over time
- Belize
- Libya
How they compare
Libya currently reports 73.9% against 73.7% in Belize, a difference of 0.2%.
The two have swapped places 2 times across 6 shared years of data; in 2000 it was Libya ahead.
Belize ranks 97th and Libya ranks 96th of 185 countries.
Across the 3 decades both report, Belize averaged higher in 1 and Libya in 2.
Head to head by decade
| Decade | Belize | Libya | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 88.0% | 91.9% | 3.9% | Libya |
| 2010s | 87.5% | 91.8% | 4.3% | Libya |
| 2020s | 78.6% | 78.3% | 0.4% | Belize |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher cause of death, by non-communicable diseases, ages 60+, female, Belize or Libya?
- Libya, at 73.9% against 73.7% in Belize as of 2021.
- What is the difference in cause of death, by non-communicable diseases, ages 60+, female between Belize and Libya?
- 0.2%, with Libya ahead.
- How many years of comparable data are there for Belize and Libya?
- 6 years are reported by both, from 2000 to 2021.
- How do Belize and Libya rank globally for cause of death, by non-communicable diseases, ages 60+, female?
- Belize ranks 97th and Libya ranks 96th of 185 countries.
- Where does this data come from?
- Global Health Estimates, World Health Organization (WHO), published as Cause of death, by non-communicable diseases, ages 60+, female (% of total female deaths ages 60+). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of female deaths ages 60+ due to non-communicable diseases divided by number of all female deaths ages 60+, expressed by percentage. Non-Communicable diseases include cancer, diabetes mellitus, cardiovascular diseases, digestive diseases, skin diseases, musculoskeletal diseases, and congenital anomalies.